Systemic Lupus Erythematosus – Pipeline Review, H2 2016

MarketResearchReports.biz has recently announced the addition of a market study “ Systemic Lupus Erythematosus – Pipeline Review, H2 2016 ”, is a comparative analysis of the global market.

Systemic Lupus Erythematosus – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus Pipeline Review, H2 2016, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 22, 31, 36 and 7 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.Systemic Lupus Erythematosus.

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/873439

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).

– The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Content

Table of Contents 2

Introduction 7

Systemic Lupus Erythematosus Overview 8

Therapeutics Development 9

Systemic Lupus Erythematosus – Therapeutics under Development by Companies 11

Systemic Lupus Erythematosus – Therapeutics under Investigation by Universities/Institutes 16

Systemic Lupus Erythematosus – Pipeline Products Glance 17

Systemic Lupus Erythematosus – Products under Development by Companies 20

Systemic Lupus Erythematosus – Products under Investigation by Universities/Institutes 27

Systemic Lupus Erythematosus – Companies Involved in Therapeutics Development 28

Systemic Lupus Erythematosus – Therapeutics Assessment 105

Drug Profiles 121

Systemic Lupus Erythematosus – Dormant Projects 381

Systemic Lupus Erythematosus – Discontinued Products 390

Systemic Lupus Erythematosus – Product Development Milestones 392

Appendix 405

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22

Number of Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 24

Number of Products under Development by Companies, H2 2016 (Contd..1) 25

Number of Products under Development by Companies, H2 2016 (Contd..2) 26

Number of Products under Development by Companies, H2 2016 (Contd..3) 27

Number of Products under Development by Companies, H2 2016 (Contd..4) 28

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Development, H2 2016 32

Products under Development by Companies, H2 2016 33

Products under Development by Companies, H2 2016 (Contd..1) 34

Products under Development by Companies, H2 2016 (Contd..2) 35

Products under Development by Companies, H2 2016 (Contd..3) 36

Products under Development by Companies, H2 2016 (Contd..4) 37

Products under Development by Companies, H2 2016 (Contd..5) 38

Products under Development by Companies, H2 2016 (Contd..6) 39

Products under Investigation by Universities/Institutes, H2 2016 40

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H2 2016 41

Systemic Lupus Erythematosus – Pipeline by Ablynx NV, H2 2016 42

Systemic Lupus Erythematosus – Pipeline by ACEA Biosciences, Inc., H2 2016 43

Systemic Lupus Erythematosus – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 44

Systemic Lupus Erythematosus – Pipeline by Actelion Ltd, H2 2016 45

Systemic Lupus Erythematosus – Pipeline by AiCuris GmbH and Co KG, H2 2016 46

Systemic Lupus Erythematosus – Pipeline by Amgen Inc., H2 2016 47

Systemic Lupus Erythematosus – Pipeline by Anthera Pharmaceuticals Inc, H2 2016 48

Systemic Lupus Erythematosus – Pipeline by Argos Therapeutics, Inc., H2 2016 49

Systemic Lupus Erythematosus – Pipeline by Asahi Kasei Pharma Corp., H2 2016 50

Systemic Lupus Erythematosus – Pipeline by Astellas Pharma Inc., H2 2016 51

Systemic Lupus Erythematosus – Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 52

Systemic Lupus Erythematosus – Pipeline by Azano Pharmaceuticals Inc., H2 2016 53

Systemic Lupus Erythematosus – Pipeline by Biogen Inc, H2 2016 54

Systemic Lupus Erythematosus – Pipeline by Biotest AG, H2 2016 55

Systemic Lupus Erythematosus – Pipeline by Boehringer Ingelheim GmbH, H2 2016 56

Systemic Lupus Erythematosus – Pipeline by Bristol-Myers Squibb Company, H2 2016 57

Systemic Lupus Erythematosus – Pipeline by Celgene Corporation, H2 2016 58

Systemic Lupus Erythematosus – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 59

Systemic Lupus Erythematosus – Pipeline by CuraVac, Inc., H2 2016 60

Systemic Lupus Erythematosus – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 61

Systemic Lupus Erythematosus – Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016 62

Systemic Lupus Erythematosus – Pipeline by Eisai Co., Ltd., H2 2016 63

Systemic Lupus Erythematosus – Pipeline by Eli Lilly and Company, H2 2016 64

Systemic Lupus Erythematosus – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 65

Systemic Lupus Erythematosus – Pipeline by Genentech Inc, H2 2016 66

Systemic Lupus Erythematosus – Pipeline by Genosco, H2 2016 67

Systemic Lupus Erythematosus – Pipeline by Genovax S.r.l., H2 2016 68

Systemic Lupus Erythematosus – Pipeline by GlaxoSmithKline Plc, H2 2016 69

Systemic Lupus Erythematosus – Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70

Systemic Lupus Erythematosus – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71

Systemic Lupus Erythematosus – Pipeline by Iltoo Pharma, H2 2016 72

Systemic Lupus Erythematosus – Pipeline by ImmuNext, Inc., H2 2016 73

Systemic Lupus Erythematosus – Pipeline by Immungenetics AG, H2 2016 74

Systemic Lupus Erythematosus – Pipeline by Immunomedics, Inc., H2 2016 75

Systemic Lupus Erythematosus – Pipeline by Immupharma Plc, H2 2016 76

Systemic Lupus Erythematosus – Pipeline by Invion Limited, H2 2016 77

Systemic Lupus Erythematosus – Pipeline by Johnson & Johnson, H2 2016 78

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest Press Releases at http://www.marketresearchreports.biz/pressreleases

Contact

State Tower

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net